Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Inclusion Criteria:

- Children eligible to be enrolled in the study are those whose parents provide written
informed consent, and are in generally good health based on the clinical judgment of
the investigators.

- Group 1 and 2 (Follow up) subjects must be 40 +/- 3 months of age at the time of
enrollment and participated in the original V59P14 study (NCT00474526).

- Group 3 and 4 (Naïve) subjects must be healthy, meningococcal vaccine-naïve children
ages 40 +/- 3 months (Group 3) or 60 +/-3 months (Group 4) at the time of enrollment,
respectively.

Exclusion Criteria:

- Serious, acute, or chronic illnesses are reasons for exclusion.

- Subjects who have received any vaccine (excluding influenza vaccines) 28 days
preceding enrollment visit. Influenza vaccines (including FluMist®) are excluded for
the 14 days prior to the enrollment visit.

- Subjects who have received any meningococcal vaccine since birth (Groups 3 & 4
-naive) or last study dose in V59P14 (NCT00474526) trial (Groups 1 & 2 - follow on).